|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The biomarker soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the cell membrane-bound protein urokinase plasminogen activator receptor (uPAR), which is expressed mainly on immune cells, endothelial cells, and smooth muscle cells. SPARCOL is a multi-center prospective observational study aiming to investigate if suPAR measured at admission can predict the risk of future complications and mortality in adults patients with Covid-19. The study will include approximately 500 patients and will be one of the largest so far. The study has been registered at Clinical Trials.gov and has been approved by the Institutional Review Board of the University Hospital of Larisa. Consecutive adult patients (≥ 18 years ) who are admitted to the Hospital due to Covid-19 will be screened for inclusion. Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark). The primary endpoint will be the presence of respiratory complications, admission to ICU, and survival at 30 days. Secondary endpoints are also included, such as organ injury, hospital length of stay, and survival. Data analysis will be based on predefined data points on a prospective data collection form.
Description: need of non-invasive ventilation (CPAP-BiPAP), hi-flow nasal oxygen, or mechanical ventilationMeasure: respiratory complications Time: Up to 8 weeks
Description: systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg for 3 minutes or moreMeasure: Hypotension Time: Up to 8 weeks
Description: need for vasoactive drugs not planned before and/or continuous infusionMeasure: need for vasoactive drugs Time: Up to 8 weeks
Description: Number of participants with atrial fibrillation, sustained ventricular tachycardia, supraventricular tachycardia, myocardial infarction, SPARCOL Study April 12, 2020 7 pericarditis, myocarditis, cardiogenic shock, and/or cardiac arrestMeasure: Number of participants with acute new cardiovascular disorder Time: Up to 8 weeks
Description: Number of participants with any organ failureMeasure: Number of participants with organ failure Time: Up to 8 weeks
Description: Number of participants who survive up to 8 weeksMeasure: Number of participants with overall survival up to 8 weeks Time: Up to 8 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports